• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Alpha Cognition Inc
BlackRock Utility, Infrastructure & Power Opportunities Trust
Liberty Global Ltd. - Class C Common Shares
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

4.670 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,019
Open 4.670
Bid (Size) 4.630 (1,000)
Ask (Size) 4.800 (200)
Prev. Close 4.670
Today's Range 4.670 - 4.670
52wk Range 3.860 - 7.005
Shares Outstanding 114,066,080
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
October 21, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
October 12, 2026
From Savara Inc.
Via Business Wire

Performance

52-Week Range 33.3% below 52-week high
4.670
3.8652W Low 7.0052W High
1 Week 6.4% below 1-week high
4.441W Low 4.991W High

Savara, Inc. - Common Stock (SVRA) traded between $3.86 and $7.00 over the past 52 weeks and last traded at $4.67, 33.3% below its 52-week high. Over the past week it ranged between $4.44 and $4.99.

Past 12 Months
-1.5%
-14.3%
-17.3%
-9.1%
-17.2%
+10.4%
1W -$0.07
1M -$0.78
3M -$0.98
6M -$0.47
YTD -$0.97
1Y +$0.44

SVRA was +10.4% over the past year, -9.1% over six months, -17.2% year to date, -1.5% in the last week.

12 Months vs Market
SVRA
+10.4%
DIA
+12.5%
SPY
+15.2%
QQQ
+18.6%
IWM
+11.9%

Over the past 12 months SVRA returned +10.4% versus DIA (Dow) +12.5%, SPY (S&P 500) +15.2%, QQQ (Nasdaq 100) +18.6% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.00× 3-mo avg
Today 1,019 3-mo avg 1.9M
1W
2.4M
1M
2.6M
3M
1.9M
6M
1.8M
YTD
1.7M
1Y
1.9M

SVRA most recently traded 1,019 shares against a 3-month average daily volume of 1.9M.

More News

Read More
News headline image
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
August 24, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
August 20, 2026
From Savara Inc.
Via Business Wire
Top movers in Tuesday's after hours session ↗
August 18, 2026
Via Chartmill
News headline image
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
July 30, 2026
From Savara Inc.
Via Business Wire
News headline image
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline ↗
June 27, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Savara Announces New Employment Inducement Grant
June 12, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Chief Financial and Administrative Officer Transition
June 08, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
May 27, 2026
From Savara Inc.
Via Business Wire
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
May 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
May 23, 2026
Via The Motley Fool
News headline image
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
May 20, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
May 19, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
May 18, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Reports First Quarter Financial Results and Provides Business Update
May 12, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
May 11, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
April 17, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
April 15, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
April 14, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
April 07, 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
March 30, 2026
From Savara Inc.
Via Business Wire
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
March 15, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
March 13, 2026
From Savara Inc.
Via Business Wire

Frequently Asked Questions

Is Savara, Inc. - Common Stock publicly traded?
Yes, Savara, Inc. - Common Stock is publicly traded.
What exchange does Savara, Inc. - Common Stock trade on?
Savara, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Savara, Inc. - Common Stock?
The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market
What is the current price of Savara, Inc. - Common Stock?
The current price of Savara, Inc. - Common Stock is 4.670
When was Savara, Inc. - Common Stock last traded?
The last trade of Savara, Inc. - Common Stock was at 10/21/26 04:00 PM ET
What is the market capitalization of Savara, Inc. - Common Stock?
The market capitalization of Savara, Inc. - Common Stock is 532.69M
How many shares of Savara, Inc. - Common Stock are outstanding?
Savara, Inc. - Common Stock has 533M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap